Table A3.

Summary of studies included in ovarian carcinoma

Estimates	Studies	Ref. No.	Design		Country		Quality
Ever vs. Never
41	40	(65,69,136–173)	Cohort	5	HIC	35	AQ	25
			Case–control	35	LMIC	5	IQ	15
<6 months vs. Never
20	19	(137,138,142,144,147–150,153,155,158,161,163,165–168,170,173)	Cohort	3	HIC	18	AQ	16
			Case–control	16	LMIC	1	IQ	3
6–12 months vs. Never
19	18	(137,138,142,144,147,148,150,153,155,158,161,163,165–168,170,173)	Cohort	2	HIC	17	AQ	15
			Case–control	16	LMIC	1	IQ	3
>12 months vs. Never
29	28	(65,69,137–140,142–144,146–148,150,152,153,155,158,161,163–168,170–173)	Cohort	3	HIC	24	AQ	23
			Case–control	25	LMIC	4	IQ	5

LIC, low-income country; AQ, adequate quality; IQ, inadequate quality.